Results 41 to 50 of about 101,617 (297)
Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26? [PDF]
CellR4, 2020 The rapid spread of SARS-CoV-2, a novel coronavirus that emerged in late 2019, and the resulting COVID-19 pandemic, has been labeled as a public health emergency of international concern by the World Health Organization.
M. Maia Pinheiro +2 more
doaj +1 more source
Heterogeneity Of Triterpenes And Steroids Structure As DPP-4 Inhibitors: A Review Article [PDF]
, 2021 Dipeptidyl peptidase-4 (DPP-4) inhibitors are diabetes mellitus drugs that inhibit the metabolism of glucagonlike peptide-1 (GLP-1) from the DPP-4 enzyme thus prolong the half-life of GLP-1.
Budipramana, Krisyanti +5 more
core
Frontiers in Pharmacology, 2017 Background and Objectives: Limited research focuses on the risk of ischemic cerebrovascular disease associated with use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with type 2 diabetes mellitus in Taiwan.
Shih-Wei Lai +7 more
doaj +1 more source
Mitochondria‐Damaging Self‐Reporting Probe for Cancer Therapy
Angewandte Chemie, EarlyView.We developed a class of self‐reporting cationic chemotherapeutic probes that selectively induce mitochondrial damage and apoptosis in cancer cells. Their unique mitochondria‐to‐nucleus fluorescence migration enables real‐time visualization of the therapeutic process. ABSTRACT Mitochondrial damage induced by chemotherapeutic agents through disruption of
Hai Xu +10 more
wiley +2 more sources
Cardiovascular Diabetology, 2018 Background Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management.
Ghadeer K. Dawwas +2 more
doaj +1 more source
Advanced Materials, EarlyView.The field of polymer thermoelectrics is entering a new era, featuring breakthroughs in addressing the conventional performance disparity between p‐type and n‐type polymers, pioneering doping frontiers, and sophisticated decoupling strategies. This review explores innovations in molecular design and superior stabilities, bridging the gap from ...
Suhao Wang
wiley +1 more source
Multicomponent Stapling of Glucagon‐Like Peptide‐1 Enables Receptor‐Guided PROTAC Delivery
Angewandte Chemie, EarlyView.We report a stapled glucagon‐like peptide‐1 (GLP‐1) analogue created via multicomponent tryptophan‐mediated Petasis reaction (TMPR). This strategy yields a stabilised peptide with superior helicity and improved potency. Conjugation to a bromodomain‐containing protein 4 (BRD4) degrader creates the first GLP‐1‐guided targeted protein degrader (PROTAC ...
Jan L. Venne +5 more
wiley +2 more sources
Role of DPP-4 inhibitors in the treatment of type 2 Diabetes [PDF]
, 2014 Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral anti-hyperglycaemic medication which enhance insulin secretion. They are considered to be a promising drug class that may meet the demands for efficacy in the treatment of type ...
Nguyen, Khanh Minh
core
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]
Endocrinology and Metabolism, 2019 BackgroundTo investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes.MethodsMEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized ...
Jae Hyun Bae +5 more
doaj +1 more source
PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe
Advanced Science, EarlyView.This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao +14 more
wiley +1 more source